ENPP3 (CD203c): An Extracellular Enzyme, a Regulator for Nucleotide and Energy, an Indicator for Allergies, an Effective Target for RCC Therapy!Lately, Xencor, Inc. has launched a clinical drug called AGS-16M8F12 (ENPP3 x CD3) to target ENPP3 in patients with metastatic renal cell carcinoma (RCC). This drug is being evaluated for its safety, pharmacokinetics, an...
Detailed information

CNR1 (CB1): A Crucial Receptor of Endocannabinoid System Offers Potential Treatments for Tumors and Glycolipid Metabolism Disorders!Denmark's Novo Nordisk recently acquired Canadian biotech firm Inversago Pharma for up to $1.075 billion. The acquisition is focused on Inversago Pharma's innovative CB1 receptor (CB1R)-based therapy, INV-202. This move ...
Detailed information

Oncostatin M (OSM): A Member of IL-6 Cytokine Family, An Underestimated Player in Future Targeted Therapies?Cytokines are molecules produced by immune cells that play a crucial role in regulating the immune response. Some cytokines are pro-inflammatory while others are anti-inflammatory. Numerous inflammation-related cytokines...
Detailed information

CDCP1: A Key Mediator for Cell Signaling in Cancers, an Emerging Target for Anti-Tumor Drugs!Recently, Nature Communications published a paper entitled "The blood proteome of imminent lung cancer diagnosis". Using a high-throughput proteomics approach, researchers at Harvard Medical School screened blood samples...
Detailed information

IL2RA (CD25): A Specific Marker of Tregs Functions as Both Immune Modulators and Targeted Agents in Various Diseases!Regulatory T cells (Tregs) are vital in immune control. On Aug 8, 2023, Innovent Biologics company published a article in Nature Cancer regarding "IL-2Rα-biased agonist boosts tumor-fighting CD25+CD8+T cells". The study...
Detailed information

BDCA2/CLEC4C: a Novel Plasma Cell-Like Dendritic Cell (pDC) Marker and Potent Inhibitor of IFN-I that Blocks SLE Development!Recently, Rheumatology published a research paper entitled "An immunomodulatory antibody-drug conjugate (ADC) targeting BDCA2 strongly suppresses pDC function and glucocorticoid responsive genes. glucocorticoid responsiv...
Detailed information

GLP-1R: An Energy Metabolism Regulator of GPCR Family, an Effective Drug Target for Type 2 Diabetes Therapy!GLP-1R, a member of the GPCR family B, has become a prominent focus in drug discovery due to its remarkable ability to regulate glucose and energy metabolism. Its pivotal role in managing diabetes and obesity, with benef...
Detailed information

DKK1: a Well-Characterized Wnt Inhibitor, a Multifunctional Regulator in Multiple Cancers!Recently, DKK1 has garnered attention in tumor therapy due to promising clinical studies. Junshi Biosciences' JS015 injection, a humanized anti-DKK1 monoclonal antibody for advanced malignant solid tumors, received IND a...
Detailed information

CEACAM6: a Potent CEA Family Molecule, a New Tumor Marker or Anti-Cancer Target!A recent article published in the American Journal of Respiratory and Critical Care Medicine reveals that CEACAM6 is a key inhibitor of HO-1 inhibitor that contributes to the development of lung disease [1]. Carcinoembry...
Detailed information

MYL9: a New Member of Myosin Motors, a Key Driver of Cancer Cell Dynamic Regulation?MYL9, the regulatory light chain of myosin, is essential for cell movement by activating myosin motility. It has been shown that MYL9 promotes cancer cell migration and is implicated in tumor development and progression....
Detailed information